Namibia Becomes 50th Country to Approve Russian Coronavirus Vaccine Sputnik V

© REUTERS / AGUSTIN MARCARIANEmpty vials of the second dose of the Sputnik V (Gam-COVID-Vac) vaccine are pictured at the San Martin hospital, in La Plata, on the outskirts of Buenos Aires, Argentina January 21, 2021.
Empty vials of the second dose of the Sputnik V (Gam-COVID-Vac) vaccine are pictured at the San Martin hospital, in La Plata, on the outskirts of Buenos Aires, Argentina January 21, 2021. - Sputnik International, 1920, 11.03.2021
Subscribe
US
India
Global
MOSCOW (Sputnik) - Namibia became the 50th country to authorise the Russian coronavirus vaccine Sputnik V, the Russian Direct Investment Fund (RDIF) said on Thursday.

"The Ministry of Health and Social Services of Namibia has registered Sputnik V under the emergency use authorisation procedure," the RDIF said in a press release.

"A new major milestone reached today for Sputnik V with 50 countries having approved the Russian vaccine, which is already saving lives and preventing the spread of coronavirus," RDIF CEO Kirill Dmitriev said, as quoted in the press release.

According to RDIF, involved in the vaccine’s distribution and promotion abroad, Sputnik V is "one of the world's top three coronavirus vaccines in terms of the number of approvals issued by government regulators".

© REUTERS / AGUSTIN MARCARIANA shipment of doses of the Sputnik V (Gam-COVID-Vac) vaccine against the coronavirus disease (COVID-19)
Namibia Becomes 50th Country to Approve Russian Coronavirus Vaccine Sputnik V  - Sputnik International, 1920, 11.03.2021
A shipment of doses of the Sputnik V (Gam-COVID-Vac) vaccine against the coronavirus disease (COVID-19)

On 11 August 2020, Russia became the first country in the world to register a vaccine against the coronavirus, dubbed Sputnik V, and developed by the Gamaleya research institute with financial support from RDIF. 

According to the analysis of phase 3 clinical trials of Sputnik V, published by The Lancet medical journal, Sputnik V has 91.6 percent efficacy against symptomatic COVID-19.

Newsfeed
0
To participate in the discussion
log in or register
loader
Chats
Заголовок открываемого материала